The Immune Microenvironment of Malignant Pleural Mesothelioma: A Literature Review
Open accessThe DOI matches its Crossref record; 158 of the 165 references it cites were found in a registry or an index.
Abstract
Malignant pleural mesothelioma (MPM) is a rare and aggressive tumour with a poor prognosis, associated with asbestos exposure. Nowadays, treatment is based on chemotherapy with a median overall survival of less than two years. This review highlights the main characteristics of the immune microenvironment in MPM with special emphasis on recent biological advances. The MPM microenvironment is highly infiltrated by tumour-associated macrophages, mainly M2-macrophages. In line with infiltration by M2-macrophages, which contribute to immune suppression, other effectors of innate immune response are deficient in MPM, such as dendritic cells or natural killer cells. On the other hand, tumour infiltrating lymphocytes (TILs) are also found in MPM, but CD4+ and CD8+ TILs might have decreased cytotoxic effects through T-regulators and high expression of immune checkpoints. Taken together, the immune microenvironment is particularly heterogeneous and can be considered as mainly immunotolerant or immunosuppressive. Therefore, identifying molecular vulnerabilities is particularly relevant to the improvement of patient outcomes and the assessment of promising treatment approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These “frustrated macrophages” release oxidative mediators and pro-inflammatory cytokines that sustain an inflamed environment and trigger signaling pathways in transformed mesothelial cells that help them to survive, despite the asbestos-related damage [31]”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [31]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Immunobiology of Dendritic Cells
Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y.-J., Pulendran, B., & Palucka, K. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.767 · Cited by 6,634 · cited 2×
“Through the secretion of IL-12, myeloid DCs induce polarization of naïve CD4+ T-cells into Th1 cells and, thus, induce a specific immune response [41].”
BackgroundCancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · cited 3×
“These cells are described in the concept of immunoediting, which reflects anti-tumour response in three phases: elimination, equilibrium and escape [89].”
BackgroundImmune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229 · cited 3×
“Immune checkpoint pathways are involved in self-tolerance and prevent tissue from damage causes by excessive immune response [99].”
BackgroundTumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033 · cited 8×
“Moreover, in vitro experiments on MT-2 human polyclonal T-cells with chronic exposure to asbestos fibres revealed that regulatory T-cells have enhanced functions through high expression of interleukin-10 and Transforming Growth Factor-betta (TGF-β) [19].”
BackgroundInfluentialTumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.136 · Cited by 3,060 · cited 1×
“Nowadays, the first-line chemotherapy for MPM is the combination of cisplatin with pemetrexed, since this combination showed efficacy versus cisplatin alone [27,28].”
BackgroundThe biology of human natural killer-cell subsets
Cooper, M. A., Fehniger, T. A., & Caligiuri, M. A. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)02060-9 · Cited by 2,975 · cited 2×
“CD56bright NKs are CD16dim or CD16- [48].”
BackgroundInnate or adaptive immunity? The example of natural killer cells
Vivier, E., Raulet, D. H., Moretta, A., Caligiuri, M. A., Zitvogel, L., Lanier, L. L., Yokoyama, W. M., & Ugolini, S. (2011) · Science · doi:10.1126/science.1198687 · Cited by 2,824 · cited 1×
“NKs express various activating (NKG2D, 2B4, NKp46) or suppressive (NKG2A, NKG2B, killer cell immunoglobulin-like receptors, CD94) receptors on their surface, which contribute to the activation or suppression of cytotoxicity [49,50].”
BackgroundInnate lymphoid cells — a proposal for uniform nomenclature
Spits, H., Artis, D., Colonna, M., Diefenbach, A., Di Santo, J. P., Eberl, G., Koyasu, S., Locksley, R. M., McKenzie, A. N. J., Mebius, R. E., et al. (2013) · Nature Reviews Immunology · doi:10.1038/nri3365 · Cited by 2,389 · cited 2×
“ILCs are divided into five groups according to cytokine production: NK cells, ILC1 (IFN-γ production as NK cells), ILC2 (IL-5, IL-13), ILC3 (IL-22, IL-17) and lymphoid tissue-inducer cells [55,56].”
BackgroundNasir, O. (2013) · Kidney and Blood Pressure Research · doi:10.1159/000350152 · Cited by 2,331
Innate Lymphoid Cells: 10 Years On
Vivier, E., Artis, D., Colonna, M., Diefenbach, A., Di Santo, J. P., Eberl, G., Koyasu, S., Locksley, R. M., McKenzie, A. N. J., Mebius, R. E., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.017 · Cited by 2,124
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917
Regulatory T cells in cancer immunotherapy
Tanaka, A., & Sakaguchi, S. (2017) · Cell Research · doi:10.1038/cr.2016.151 · Cited by 1,860 · cited 2×
“As a consequence, high infiltration of Tregs within the tumour is associated with a poor prognosis [61].”
BackgroundCorrales, L., Glickman, L. H., McWhirter, S. M., Kanne, D. B., Sivick, K. E., Katibah, G. E., Woo, S.-R., Lemmens, E., Banda, T., Leong, J. J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.031 · Cited by 1,560
Cancer despite immunosurveillance: immunoselection and immunosubversion
Zitvogel, L., Tesniere, A., & Kroemer, G. (2006) · Nature reviews. Immunology · doi:10.1038/nri1936 · Cited by 1,324 · cited 3×
“Memory T-cells are responsible for secondary response: 1) central memory T-cells remain in lymphoid tissues and express CCR7 and CD45RO on their surface, and 2) memory T-cells in tissues lack of CCR7 expression and express CCR3, CCR5 and CD45RO on their surface [60].”
BackgroundGermline BAP1 Mutations Predispose to Malignant Mesothelioma
Testa, J. R., Cheung, M., Pei, J., Below, J. E., Tan, Y., Sementino, E., Cox, N. J., Dogan, A. U., Pass, H. I., Trusa, S., et al. (2011) · Nature Genetics · doi:10.1038/ng.912 · Cited by 1,076 · cited 1×
“abnormalities involved in the development of MPM are germline BAP1 (breast cancer 1-BRCA1-associated protein (1) mutation, resulting in the loss of expression of BAP1, described in familial cases of mesothelioma [21].”
BackgroundZalcman, G., Mazieres, J., Margery, J., Greillier, L., Audigier-Valette, C., Moro-Sibilot, D., Molinier, O., Corre, R., Monnet, I., Gounant, V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01238-6 · Cited by 968 · cited 1×
“001), when adding bevacizumab to cisplatin-pemetrexed [29] and, therefore, the ERS/ESTS/EACTS/ESTRO 2020 guidelines suggested that bevacizumab should be proposed in combination with cisplatin-pemetrexed as first-line treatment [30].”
BackgroundBueno, R., Stawiski, E. W., Goldstein, L. D., Durinck, S., De Rienzo, A., Modrusan, Z., Gnad, F., Nguyen, T. T., Jaiswal, B. S., Chirieac, L. R., et al. (2016) · Nature Genetics · doi:10.1038/ng.3520 · Cited by 919
Targeting the EGFR signaling pathway in cancer therapy
Seshacharyulu, P., Ponnusamy, M. P., Haridas, D., Jain, M., Ganti, A. K., & Batra, S. K. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.648617 · Cited by 913 · cited 1×
“The therapeutic functions can be emphasized by targeting certain surface Ags of lymphocytes, such as CD40 [64], CD20 [65], CD19 [66], CD73 [67], CTLA-4 or PD-1 immune checkpoints [68], blocking the binding of specific ligands, and perturbing the EGFR and HER2 signaling pathways [69,70].”
BackgroundThe European mesothelioma epidemic
Peto, J., Decarli, A., Vecchia, C. L., Levi, F., & Negri, E. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690105 · Cited by 891
Advances in Malignant Mesothelioma
Robinson, B. W. S., & Lake, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050152 · Cited by 889 · cited 3×
“Asbestos carcinogenesis is ainly due to four ain processes [7,11].”
BackgroundHendry, S., Salgado, R., Gevaert, T., Russell, P. A., John, T., Thapa, B., Christie, M., van de Vijver, K., Estrada, M. V., Gonzalez-Ericsson, P. I., et al. (2017) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000161 · Cited by 799 · cited 10×
“In this model, depletion of FOXP3 was associated with upregulation of immune checkpoint expression (PD-1 and CTLA-4) on CD4+ and CD8+ TILs and a central memory T-cells pattern (CD44 + CD62L + CD4+ T-cells and CD44 + CD62L + CD8+ T-cells) [86].”
BackgroundInfluentialThe emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses
Walker, L. S. K., & Sansom, D. M. (2011) · Nature Reviews Immunology · doi:10.1038/nri3108 · Cited by 786
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
Wang, L., Rubinstein, R., Lines, J. L., Wasiuk, A., Ahonen, C., Guo, Y., Lu, L.-F., Gondek, D., Wang, Y., Fava, R. A., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20100619 · Cited by 710
Promotion of Tissue Inflammation by the Immune Receptor Tim-3 Expressed on Innate Immune Cells
Anderson, A. C., Anderson, D. E., Bregoli, L., Hastings, W. D., Kassam, N., Lei, C., Chandwaskar, R., Karman, J., Su, E. W., Hirashima, M., et al. (2007) · Science · doi:10.1126/science.1148536 · Cited by 701
Robinson, B. W., Musk, A. W., & Lake, R. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67025-0 · Cited by 664
Integrative Molecular Characterization of Malignant Pleural Mesothelioma
Hmeljak, J., Sanchez-Vega, F., Hoadley, K. A., Shih, J., Stewart, C., Heiman, D., Tarpey, P., Danilova, L., Drill, E., Gibb, E. A., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0804 · Cited by 618
Gao, J., Ward, J. F., Pettaway, C. A., Shi, L. Z., Subudhi, S. K., Vence, L. M., Zhao, H., Chen, J., Chen, H., Efstathiou, E., et al. (2017) · Nature Medicine · doi:10.1038/nm.4308 · Cited by 594
Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy
Picarda, E., Ohaegbulam, K. C., & Zang, X. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2428 · Cited by 582
Curran, D., Sahmoud, T., Therasse, P., van Meerbeeck, J., Postmus, P. E., & Giaccone, G. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.145 · Cited by 543 · cited 1×
“demonstrated that sarcomatoid sub-type, as well as poor performance status, high white blood count and male gender, are associated with poor prognosis [9].”
BackgroundCancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine Production
Clayton, A., Al-Taei, S., Webber, J., Mason, M. D., & Tabi, Z. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003884 · Cited by 540
Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors
Morello, A., Sadelain, M., & Adusumilli, P. S. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0583 · Cited by 477
Scherpereel, A., Mazieres, J., Greillier, L., Lantuejoul, S., Dô, P., Bylicki, O., Monnet, I., Corre, R., Audigier-Valette, C., Locatelli-Sanchez, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30765-4 · Cited by 454
Proteomic Analysis of Exosomes Isolated from Human Malignant Pleural Effusions
Bard, M. P., Hegmans, J. P., Hemmes, A., Luider, T. M., Willemsen, R., Severijnen, L.-A. A., van Meerbeeck, J. P., Burgers, S. A., Hoogsteden, H. C., & Lambrecht, B. N. (2004) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2003-0238oc · Cited by 416
Goldberg, M. V., & Drake, C. G. (2010) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2010_114 · Cited by 337
STING pathway agonism as a cancer therapeutic
Flood, B. A., Higgs, E. F., Li, S., Luke, J. J., & Gajewski, T. F. (2019) · Immunological Reviews · doi:10.1111/imr.12765 · Cited by 334
High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma
Nasu, M., Emi, M., Pastorino, S., Tanji, M., Powers, A., Luk, H., Baumann, F., Zhang, Y.-A., Gazdar, A., Kanodia, S., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000471 · Cited by 326 · cited 1×
“In addition, somatic BAP1 alteration occurs in almost 60% of sporadic MPM [22].”
BackgroundNovel Insights into Mesothelioma Biology and Implications for Therapy
Yap, T. A., Aerts, J. G., Popat, S., & Fennell, D. A. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.42 · Cited by 324 · cited 4×
“Asbestos carcinogenesis is ainly due to four ain processes [7,11].”
BackgroundInfluentialYang, H., Bocchetta, M., Kroczynska, B., Elmishad, A. G., Chen, Y., Liu, Z., Bubici, C., Mossman, B. T., Pass, H. I., Testa, J. R., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604008103 · Cited by 322
Kao, S. C. H., Pavlakis, N., Harvie, R., Vardy, J. L., Boyer, M. J., van Zandwijk, N., & Clarke, S. J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2245 · Cited by 316 · cited 3×
“Kao, 2010 [94] 173 NLR and OS Chemotherapy and chemotherapy naïve patients NLR < 5 associated with better OS in chemotherapy group and chemotherapy-naïve group Normalization of NLR ratio after one cycle of chemotherapy associated with a better OS”
BackgroundResultInfluentialPrimary T Cell Expansion and Differentiation In Vivo Requires Antigen Presentation by B Cells
Crawford, A., MacLeod, M., Schumacher, T., Corlett, L., & Gray, D. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.6.3498 · Cited by 313 · cited 2×
“B cells may act as antibody-generator or antigenpresenting cells (APCs).”
BackgroundPhase II Study of Pemetrexed Plus Carboplatin in Malignant Pleural Mesothelioma
Ceresoli, G. L., Zucali, P. A., Favaretto, A. G., Grossi, F., Bidoli, P., Del Conte, G., Ceribelli, A., Bearz, A., Morenghi, E., Cavina, R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3190 · Cited by 296 · cited 1×
“Nowadays, the first-line chemotherapy for MPM is the combination of cisplatin with pemetrexed, since this combination showed efficacy versus cisplatin alone [27,28].”
BackgroundExtracellular vesicles in the tumor microenvironment: old stories, but new tales
Han, L., Lam, E. W.-F., & Sun, Y. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0980-8 · Cited by 294
Galateau-Salle, F., Churg, A., Roggli, V., & Travis, W. D. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.11.005 · Cited by 282 · cited 2×
“sarcomatoid histologies (20% of cases), with 10% of cases remaining indeterminate [7,8].”
BackgroundMolecular pathogenesis of malignant mesothelioma
Sekido, Y. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt166 · Cited by 279
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
Scherpereel, A., Opitz, I., Berghmans, T., Psallidas, I., Glatzer, M., Rigau, D., Astoul, P., Bölükbas, S., Boyd, J., Coolen, J., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00953-2019 · Cited by 273
VSIG‐3 as a ligand of VISTA inhibits human T‐cell function
Wang, J., Wu, G., Manick, B., Hernandez, V., Renelt, M., Erickson, C., Guan, J., Singh, R., Rollins, S., Solorz, A., et al. (2019) · Immunology · doi:10.1111/imm.13001 · Cited by 263
Zanella, C. L., Posada, J. A., Tritton, T. R., & Mossman, B. T. (1996) · PubMed · Cited by 256
Lin, R.-T., Takahashi, K., Karjalainen, A., Hoshuyama, T., Wilson, D., Kameda, T., Chan, C.-C., Wen, C.-P., Furuya, S., Higashi, T., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60412-7 · Cited by 239
Mansfield, A. S., Roden, A. C., Peikert, T., Sheinin, Y. M., Harrington, S. M., Krco, C. J., Dong, H., & Kwon, E. D. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000177 · Cited by 238 · cited 3×
“Indeed, immunohistochemistry analysis (Figure 7) of 106 patient samples with an MPM, showed that 40% of them expressed PD-L1 ≥ 5% [102].”
BackgroundInfluentialMalignant pleural mesothelioma: an epidemiological perspective.
Robinson, B. M. (2012) · PubMed · doi:10.3978/j.issn.2225-319x.2012.11.04 · Cited by 237
Kakavand, H., Jackett, L. A., Menzies, A. M., Gide, T. N., Carlino, M. S., Saw, R. P. M., Thompson, J. F., Wilmott, J. S., Long, G. V., & Scolyer, R. A. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.89 · Cited by 223
Cedrés, S., Ponce-Aix, S., Zugazagoitia, J., Sansano, I., Enguita, A., Navarro-Mendivil, A., Martinez-Marti, A., Martinez, P., & Felip, E. (2015) · PLOS ONE · doi:10.1371/journal.pone.0121071 · Cited by 219 · cited 4×
“Cedrés, 2015 [103] 77 PD-L1 and overall survival (OS) Tissue biopsy immunohistoche mistry PD-L1 > 1% PD-L1 positive cases were associated with poor OS”
BackgroundResultInfluentialActivated B cells express functional Fas ligand
Hahne, M., Renno, T., Schroeter, M., Irmler, M., French, L., Bornand, T., MacDonald, H. R., & Tschopp, J. (1996) · European Journal of Immunology · doi:10.1002/eji.1830260332 · Cited by 201 · cited 1×
“The mechanism of action is the expression, by some B lymphocytes, of the death-inducing molecule Fas ligand (FasL), which kills cells directly [73,74].”
BackgroundImmunoregulatory functions of VISTA
Nowak, E. C., Lines, J. L., Varn, F. S., Deng, J., Sarde, A., Mabaera, R., Kuta, A., Le Mercier, I., Cheng, C., & Noelle, R. J. (2017) · Immunological Reviews · doi:10.1111/imr.12525 · Cited by 197
Gao, Z.-W., Dong, K., & Zhang, H.-Z. (2014) · BioMed Research International · doi:10.1155/2014/460654 · Cited by 195 · cited 2×
“MPM-derived exosome in pleural effusion express CD39 and CD73—receptors that are known to produce extracellular adenosine and promote downregulation of T-cells functions—which highlights, as well, that exosome contributes to harness T-cells functions [145].”
BackgroundRegulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice
Horikawa, M., Minard-Colin, V., Matsushita, T., & Tedder, T. F. (2011) · Journal of Clinical Investigation · doi:10.1172/jci59266 · Cited by 191 · cited 1×
“Despite these effects of B cells that inhibit tumour development, it was shown that B cells have functions in suppressing immune response through several ways, with Bregs being the dominant element [75].”
BackgroundAn, X., Zhu, Y., Zheng, T., Wang, G., Zhang, M., Li, J., Ji, H., Li, S., Yang, S., Xu, D., et al. (2019) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2018.11.003 · Cited by 188
Establishment of a murine model of malignant mesothelioma
Davis, M. R., Manning, L. S., Whitaker, D., Garlepp, M. J., & Robinson, B. W. S. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910520609 · Cited by 186 · cited 1×
“In CD1d wild-type xenograft models, after sub-cutaneous injection of AB12 cell lines—a murine malignant mesothelioma cell line derived from asbestos-induced tumour in Balb/c mice [52]—tumour growth was decreased by the combination of α-GC following each cycle of cisplatin [51].”
BackgroundDiffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province
Wagner, J. C., Sleggs, C. A., & Marchand, P. (1960) · Occupational and Environmental Medicine · doi:10.1136/oem.17.4.260 · Cited by 182
Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma
Anraku, M., Cunningham, K. S., Yun, Z., Tsao, M., Li, Z., Keshavjee, S. H., Johnston, M. R., & de Perrot, M. E. (2008) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2007.10.026 · Cited by 171
Yamada, N., Oizumi, S., Kikuchi, E., Shinagawa, N., Konishi-Sakakibara, J., Ishimine, A., Aoe, K., Gemba, K., Kishimoto, T., Torigoe, T., et al. (2010) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-010-0881-6 · Cited by 169 · cited 3×
“can be used as a prognosis biomarker for patients who underwent extrapleural pneumonectomy for an MPM [82].”
BackgroundInfluentialNovel therapies for malignant pleural mesothelioma
Scherpereel, A., Wallyn, F., Albelda, S. Μ., & Munck, C. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30100-1 · Cited by 163
Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses
Hegmans, J. P. J. J., Hemmes, A., Hammad, H., Boon, L., Hoogsteden, H. C., & Lambrecht, B. N. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00135305 · Cited by 162 · cited 5×
“found high level of CD4 + CD25 + FOXP3+ Tregs in the vicinity of the tumour of human MPM samples [33].”
BackgroundMethodInfluentialRegulatory B cells accelerate hepatocellular carcinoma progression via CD40/CD154 signaling pathway
Shao, Y., Lo, C. M., Ling, C. C., Liu, X. B., Ng, K. T.-P., Chu, A. C. Y., Ma, Y. Y., Li, C. X., Fan, S. T., & Man, K. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.09.026 · Cited by 158 · cited 1×
“Indeed, Bregs seem to attenuate immune response in cancers [76,77], but also in other inflammatory diseases [78], activated through the TLR, BCR, CD40/CD40L or B-cell activating factor (BAFF) -signaling pathways.”
BackgroundMesothelioma incidence in 50 states and the District of Columbia, United States, 2003–2008
Jane Henley, S., Larson, T. C., Wu, M., Antao, V. C. S., Lewis, M., Pinheiro, G. A., & Eheman, C. (2013) · International Journal of Occupational and Environmental Health · doi:10.1179/2049396712y.0000000016 · Cited by 157
Exosomes and the MICA-NKG2D system in cancer
Clayton, A., & Tabi, Z. (2005) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2005.03.003 · Cited by 149
BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma
Shrestha, R., Nabavi, N., Lin, Y.-Y., Mo, F., Anderson, S., Volik, S., Adomat, H. H., Lin, D., Xue, H., Dong, X., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0620-3 · Cited by 147
The soluble isoform of CTLA‐4 as a regulator of T‐cell responses
Ward, F. J., Dahal, L. N., Wijesekera, S. K., Abdul-Jawad, S., Kaewarpai, T., Xu, H., Vickers, M. A., & Barker, R. N. (2013) · European Journal of Immunology · doi:10.1002/eji.201242529 · Cited by 142
Ujiie, H., Kadota, K., Nitadori, J.-I., Aerts, J. G., Woo, K. M., Sima, C. S., Travis, W. D., Jones, D. R., Krug, L. M., & Adusumilli, P. S. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1009285 · Cited by 135 · cited 4×
“[38] found a similar result as previously described by Chee et al.”
BackgroundResultInfluentialCho, J., Feld, R., Leighl, N. B., Opitz, I., Anraku, M., Tsao, M., Hwang, D. M., Hope, A. J., & de Perrot, M. E. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000078 · Cited by 135 · cited 1×
“In addition, in patients with resectable MPM included in the SMART trial (Surgery for Mesothelioma after Radiation Therapy) [85] evaluating a short, accelerated course of high-dose hemithoracic intensity-modulated radiation therapy followed by extrapleural pneumonectomy, FOXP3+ Tregs were found to be increased after i…”
BackgroundCTLA-4 Overexpression Inhibits T Cell Responses through a CD28-B7-Dependent Mechanism
Engelhardt, J. J., Sullivan, T. J., & Allison, J. P. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.2.1052 · Cited by 135
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
Opitz, I., Scherpereel, A., Berghmans, T., Psallidas, I., Glatzer, M., Comas, D. R., Astoul, P. J., Bölükbas, S., Boyd, J., Coolen, J., et al. (2020) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezaa158 · Cited by 121 · cited 1×
“001), when adding bevacizumab to cisplatin-pemetrexed [29] and, therefore, the ERS/ESTS/EACTS/ESTRO 2020 guidelines suggested that bevacizumab should be proposed in combination with cisplatin-pemetrexed as first-line treatment [30].”
BackgroundMahaweni, N. M., Kaijen‐Lambers, M. E. H., Dekkers, J., Aerts, J. G. J. V., & Hegmans, J. P. J. J. (2013) · Journal of Extracellular Vesicles · doi:10.3402/jev.v2i0.22492 · Cited by 119
Circulating and Tumor-Infiltrating Myeloid Cells Predict Survival in Human Pleural Mesothelioma
Burt, B. M., Rodig, S. J., Tilleman, T. R., Elbardissi, A. W., Bueno, R., & Sugarbaker, D. J. (2011) · Cancer · doi:10.1002/cncr.26143 · Cited by 115 · cited 5×
“High standard deviation indicates heterogeneity in macrophage infiltration [34,35].”
BackgroundInfluentialKamp, D. W., Israbian, V. A., Preusen, S. E., Zhang, C. X., & Weitzman, S. A. (1995) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.1995.268.3.l471 · Cited by 112 · cited 1×
“Asbestos fibres may also induce the production of iron-related reactive oxygen species, which results in DNA damage [16].”
BackgroundKhanna, S., Thomas, A., Abate‐Daga, D., Zhang, J., Morrow, B., Steinberg, S. M., Orlandi, A., Ferroni, P., Schlom, J., Guadagni, F., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.07.033 · Cited by 111
Pasello, G., Zago, G., Lunardi, F., Urso, L., Kern, I., Vlacic, G., Grosso, F., Mencoboni, M., Ceresoli, G. L., Schiavon, M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy086 · Cited by 107 · cited 4×
“[80] observed in chemonaive MPM samples that sarcomatoid/biphasic MPM were characterized by high CD8+ TILs, whereas epithelioid MPM expressed higher peri-tumoral CD4+ T-cells and CD20+ B cells.”
BackgroundInfluentialImmunotherapy of Murine Malignant Mesothelioma Using Tumor Lysate–pulsed Dendritic Cells
Hegmans, J. P. J. J., Hemmes, A., Aerts, J. G., Hoogsteden, H. C., & Lambrecht, B. N. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200501-057oc · Cited by 106 · cited 3×
“Pulsed DCs have shown interesting results in pre-clinical models as they prevented tumour outgrowth [44].”
BackgroundResultMuller, S., Victoria Lai, W., Adusumilli, P. S., Desmeules, P., Frosina, D., Jungbluth, A., Ni, A., Eguchi, T., Travis, W. D., Ladanyi, M., et al. (2020) · Modern Pathology · doi:10.1038/s41379-019-0364-z · Cited by 106
Cornelissen, R., Hegmans, J. P. J. J., Maat, A. P. W. M., Kaijen-Lambers, M. E. H., Bezemer, K., Hendriks, R. W., Hoogsteden, H. C., & Aerts, J. G. J. V. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201508-1573oc · Cited by 105
Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo
Greening, D. W., Ji, H. L., Chen, M., Robinson, B. W. S., Dick, I. M., Creaney, J., & Simpson, R. J. (2016) · Scientific Reports · doi:10.1038/srep32643 · Cited by 105
Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials
Hassan, S. B., Sørensen, J. F., Olsen, B. N., & Pedersen, A. E. (2014) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2014.890626 · Cited by 103 · cited 4×
“DCs also seem to be functionally deficient in mesotheliomas, as assessed by the lower expression of costimulatory (CD40, Figure 3.”
BackgroundInfluentialDiffuse Mesothelioma of the Pleura and Asbestos
Elmes, P. C., McCaughey, W. T. E., & Wade, O. L. (1965) · BMJ · doi:10.1136/bmj.1.5431.350 · Cited by 103
Anti-Mesothelin CAR T cell therapy for malignant mesothelioma
Castelletti, L., Yeo, D., van Zandwijk, N., & Rasko, J. E. J. (2021) · Biomarker Research · doi:10.1186/s40364-021-00264-1 · Cited by 102
Fleury‐Feith, J., Boulangé-Lecomte, C., Renier, A., Matrat, M., Kheuang, L., Abramowski, V., Levy, F., Janin, A., Giovannini, M., & Jaurand, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206593 · Cited by 100
Pleural Plaques and the Risk of Pleural Mesothelioma
Pairon, J.-C., Laurent, F., Rinaldo, M., Clin, B., Andujar, P., Ameille, J., Brochard, P., Chammings, S., Ferretti, G., Galateau-Sallé, F., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs513 · Cited by 100 · cited 1×
“Although the relationship between asbestos exposure and MPM has been proven for a long time, a total of only 17 incident cases of malignant mesothelioma were diagnosed among 5287 patients previously exposed to asbestos during a 7-year follow-up study [20].”
BackgroundParker Harp, C. R., Archambault, A. S., Sim, J., Ferris, S. T., Mikesell, R. J., Koni, P. A., Shimoda, M., Linington, C., Russell, J. H., & Wu, G. F. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402236 · Cited by 97 · cited 1×
“B cells can also promote anti-tumor immunity through providing Ags to both CD4+ and CD8+ T cells [71] or through cross-presentation of Ags to other APCs [72].”
BackgroundImmune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas
Combaz-Lair, C., Galateau-Sallé, F., Leer, A. M., Stang, N. L., David‐Boudet, L., Duruisseaux, M., Ferretti, G., Brambilla, E. M., Lebecque, S., & Lantuéjoul, S. (2016) · Human Pathology · doi:10.1016/j.humpath.2016.01.010 · Cited by 97
Kaltenmeier, C., Gawanbacht, A., Beyer, T., Lindner, S., Trzaska, T., van der Merwe, J. A., Härter, G., Grüner, B., Fabricius, D., Lotfi, R., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402568 · Cited by 93 · cited 1×
“Indeed, Bregs seem to attenuate immune response in cancers [76,77], but also in other inflammatory diseases [78], activated through the TLR, BCR, CD40/CD40L or B-cell activating factor (BAFF) -signaling pathways.”
BackgroundKao, S. C.-H., Klebe, S., Henderson, D. W., Reid, G., Chatfield, M. D., Armstrong, N. J., Yan, T. D., Vardy, J. L., Clarke, S. J., van Zandwijk, N., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31822a3740 · Cited by 92 · cited 1×
“Kao, 2011 [95] 85 NLR and OS Patients with extrapleural pneumonectomy NLR ≥ 3 was associated with poor OS in patients with extrapleural pneumonectomy”
BackgroundCornelissen, R., Lievense, L. A., Maat, A. P., Hendriks, R. W., Hoogsteden, H. C., Bogers, A. J., Hegmans, J. P., & Aerts, J. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106742 · Cited by 91 · cited 4×
“, 2014 [39] 16 Intratumor CD8, total macrophages, M2 and OS Immunohistochemistry Comparison CT induction + surgery vs.”
BackgroundInfluentialAerts, J. G. J. V., de Goeje, P. L., Cornelissen, R., Kaijen-Lambers, M. E. H., Bezemer, K., van der Leest, C. H., Mahaweni, N. M., Kunert, A., Eskens, F. A. L. M., Waasdorp, C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2522 · Cited by 91
Immunotherapy in Malignant Pleural Mesothelioma
de Gooijer, C. J., Borm, F. J., Scherpereel, A., & Baas, P. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00187 · Cited by 90
Behavior of crocidolite asbestos during mitosis in living vertebrate lung epithelial cells.
Ault, J. G., Cole, R. W., Jensen, C. G., Jensen, L. C. W., Bachert, L. A., & Rieder, C. L. (1995) · PubMed · Cited by 89
Marcq, E., Siozopoulou, V., De Waele, J., van Audenaerde, J., Zwaenepoel, K., Santermans, E., Hens, N., Pauwels, P., van Meerbeeck, J. P., & Smits, E. L. J. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1261241 · Cited by 88 · cited 9×
“, 2017 [40] 54 CD68, PD-L1, TIM-3, CD4, CD8, CD45RO Immunohistochemistry tissue biopsies High CD4+ is associated with better survival Increase in the CD45RO expression on stromal lymphocytes was significantly associated with a lower likelihood of partial or complete response to chemotherapy”
BackgroundInfluentialTumino, N., Martini, S., Munari, E., Scordamaglia, F., Besi, F., Mariotti, F. R., Bogina, G. S., Mingari, M. C., Vacca, P., & Moretta, L. (2019) · International Journal of Cancer · doi:10.1002/ijc.32262 · Cited by 87 · cited 5×
“, 2019 [57] 33 NK cells Innate lymphoid cells (ILC) 1,2,3 Pleural fluid Flow cytometry NK highly expressed ILC3 more highly expressed than ILC2 and ILC1”
BackgroundMethodInfluentialB7-H3 Immune Checkpoint Protein in Human Cancer
Karlsen, K. F., Fodstad, Ø., & Nunes‐Xavier, C. E. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190517115515 · Cited by 87
Zheng, Y., Manzotti, C. N., Burke, F., Dussably, L., Qureshi, O., Walker, L. S. K., & Sansom, D. M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.3.1683 · Cited by 86
STING, a promising target for small molecular immune modulator: A review
Liu, Y., Lü, X., Qin, N., Qiao, Y., Xing, S., Liu, W., Feng, F., Liu, Z., & Sun, H. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113113 · Cited by 84
Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions
Alcala, N., Mangiante, L., Le-Stang, N., Gustafson, C. E., Boyault, S., Damiola, F., Alcala, K., Brevet, M., Thivolet-Bejui, F., Blanc-Fournier, C., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.09.003 · Cited by 77
Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma
Ladanyi, M., Sánchez-Vega, F., & Zauderer, M. G. (2019) · Genome Medicine · doi:10.1186/s13073-019-0631-0 · Cited by 74
Awad, M. M., Jones, R. E., Liu, H., Lizotte, P. H., Ivanova, E. V., Kulkarni, M., Herter-Sprie, G. S., Liao, X., Santos, A. A., Bittinger, M. A., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0171 · Cited by 73 · cited 4×
“Awad, 2016 [105] 43 PD-L1, CD4+, CD8+, TIMP3, CD45+ and overall survival (OS) Surgically resected MPM Next generation sequencing Flow cytometry PD-L1 positive cases were associated with CD4+, CD8+, TIM3, CD45+ positive cases No difference in survival according to PD-L1 status Figure 8.”
BackgroundResultInfluentialHeterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma
Minnema-Luiting, J., Vroman, H., Aerts, J., & Cornelissen, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041041 · Cited by 73 · cited 8×
“M2-macrophages are important cells as they are associated with the immune-suppressive function of CD8+ cells through the secretion of arginase and several cytokines [35,36].”
BackgroundResultInfluentialThe Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy
Chu, G. J., van Zandwijk, N., & Rasko, J. E. J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01366 · Cited by 70 · cited 5×
“It is estimated that TILs represent an average of 20 to 42 of the i une cell infiltration in MPM [58].”
BackgroundInfluentialNishimura, Y., Miura, Y., Maeda, M., Kumagai, N., Murakami, S., Hayashi, H., Fukuoka, K., Nakano, T., & Otsuki, T. (2009) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463200902200304 · Cited by 69 · cited 5×
“The authors showed that patients with an MPM have lower cytotoxicity of NKs in comparison with healthy-matched controls, as assessed by a decreased expression of the activating receptor NKp46 [49].”
BackgroundInfluentialKiyotani, K., Park, J.-H., Inoue, H., Husain, A., Olugbile, S., Zewde, M., Nakamura, Y., & Vigneswaran, W. T. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1278330 · Cited by 69 · cited 16×
“In this model, depletion of FOXP3 was associated with upregulation of immune checkpoint expression (PD-1 and CTLA-4) on CD4+ and CD8+ TILs and a central memory T-cells pattern (CD44 + CD62L + CD4+ T-cells and CD44 + CD62L + CD8+ T-cells) [86].”
MethodInfluentialEvaluating the effect of immune cells on the outcome of patients with mesothelioma
Chee, S. J., Lopez, M., Mellows, T., Gankande, S., Moutasim, K. A., Harris, S., Clarke, J., Vijayanand, P., Thomas, G. J., & Ottensmeier, C. H. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.269 · Cited by 69 · cited 4×
“Their results showed that in the epithelioid group, high CD4+, CD20+ and low FOXP3+ and NP57+ are associated with a better outcome, whereas, in the nonepithelioid group, only low FOXP3 expression was significant [84].”
BackgroundMethodInfluentialPrognostic Factors in Patients Presenting with Pleural Effusion Revealing Malignancy
Anevlavis, S., Kouliatsis, G., Sotiriou, I., Koukourakis, M. I., Archontogeorgis, K., Karpathiou, G., Giatromanolaki, A. N., & Froudarakis, Μ. E. (2014) · Respiration · doi:10.1159/000356764 · Cited by 68
Self-citationPotential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma
Salaroglio, I. C., Kopecka, J., Napoli, F., Pradotto, M., Maletta, F., Costardi, L., Gagliasso, M., Milosevic, V., Ananthanarayanan, P., Bironzo, P., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.03.029 · Cited by 68 · cited 10×
“, 2019 [37] 275 Intrapleural and Intratumor T-regs, M2, MDSC, TILs and OS, PFS Pleural fluid and pleural biopsies by flow cytometry MDSC related to anergy of TILs.”
BackgroundInfluentialLymphocytic infiltration of pleural mesothelioma and its significance for survival.
Ra, L., & Webster, I. (1982) · PubMed · Cited by 67
Positive and negative functions of B lymphocytes in tumors
Shen, M., Sun, Q., Wang, J., Pan, W., & Ren, X. (2016) · Oncotarget · doi:10.18632/oncotarget.10094 · Cited by 64 · cited 3×
“By producing these cytokines, B cells can interplay with other immunocytes, such as T cells, DCs, macrophages, and natural killer (NK) cells and further influence their functions [63].”
BackgroundInfluentialKarpathiou, G., Stefanou, D., & Froudarakis, Μ. E. (2015) · Respiratory Medicine · doi:10.1016/j.rmed.2015.05.014 · Cited by 62 · cited 2×
“Indeed, an interaction exists between asbestos fibres with mesothelial and inflammatory cells, releasing macrophages, cytokines and growth factors, which promote chronic inflammation and tumour growth [13,14].”
BackgroundSelf-citationEnhanced frequency and potential mechanism of B regulatory cells in patients with lung cancer
Zhou, J., Min, Z., Zhang, D., Wang, W., Marincola, F., & Wang, X. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0304-0 · Cited by 62 · cited 1×
“Indeed, Bregs seem to attenuate immune response in cancers [76,77], but also in other inflammatory diseases [78], activated through the TLR, BCR, CD40/CD40L or B-cell activating factor (BAFF) -signaling pathways.”
BackgroundYamagishi, T., Fujimoto, N., Nishi, H., Miyamoto, Y., Hara, N., Asano, M., Fuchimoto, Y., Wada, S., Kitamura, K., Ozaki, S., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.07.014 · Cited by 61 · cited 3×
“were interested in blood samples of 150 consecutive patients diagnosed with MPM [98].”
BackgroundMethodInfluentialBurgio, S., Noori, L., Marino Gammazza, A., Campanella, C., Logozzi, M., Fais, S., Bucchieri, F., Cappello, F., & Caruso Bavisotto, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155432 · Cited by 58
Malignant Pleural Mesothelioma: From the Bench to the Bedside
Astoul, P. J., Roca, E., Galateau-Sallé, F., & Scherpereel, A. (2012) · Respiration · doi:10.1159/000339259 · Cited by 57 · cited 2×
“Indeed, they showed that pulsed DCs, with AB1 tumour mesothelioma cell line lysate, AB1-derived exosomes or ex vivo AB1 tumour lysate, could prevent the outgrowth of mesothelioma following tumour implantation in a mouse model [31,44].”
BackgroundMarcq, E., Waele, J. D., Audenaerde, J. V., Lion, E., Santermans, E., Hens, N., Pauwels, P., van Meerbeeck, J. P., & Smits, E. L. J. (2017) · Oncotarget · doi:10.18632/oncotarget.21113 · Cited by 57 · cited 6×
“, PD-1, LAG-3 and TIM-3) in flow-cytometry analysis of pleural effusion [45].”
BackgroundInfluentialon behalf of the DENIM team*, Belderbos, R. A., Baas, P., Berardi, R., Cornelissen, R., Fennell, D. A., van Meerbeeck, J. P., Scherpereel, A., Vroman, H., & Aerts, J. G. J. V. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.05.05 · Cited by 55
Baas, P., Scherpereel, A., Nowak, A. K., Fujimoto, N., Peters, S., Tsao, A. S., Mansfield, A. S., Popat, S., Jahan, T. M., Antonia, S. J., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.08.004 · Cited by 53
Roncella, S., Laurent, S., Fontana, V., Ferro, P., Franceschini, M. C., Salvi, S., Varesano, S., Boccardo, S., Vigani, A., Morabito, A., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1844-3 · Cited by 52
Exosomal miR-16-5p as a target for malignant mesothelioma
Munson, P. B., Hall, E. M., Farina, N. H., Pass, H. I., & Shukla, A. (2019) · Scientific Reports · doi:10.1038/s41598-019-48133-0 · Cited by 51
33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)
(2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0423-x · Cited by 49
Tumor immune microenvironment characterization and response to anti-PD-1 therapy.
Santarpía, M., & Karachaliou, N. (2015) · PubMed · doi:10.7497/j.issn.2095-3941.2015.0022 · Cited by 47 · cited 1×
“The therapeutic functions can be emphasized by targeting certain surface Ags of lymphocytes, such as CD40 [64], CD20 [65], CD19 [66], CD73 [67], CTLA-4 or PD-1 immune checkpoints [68], blocking the binding of specific ligands, and perturbing the EGFR and HER2 signaling pathways [69,70].”
BackgroundHuman NK cells: From surface receptors to clinical applications
Moretta, L., Pietra, G., Vacca, P., Pende, D., Moretta, F., Bertaina, A., Mingari, M. C., Locatelli, F., & Moretta, A. (2016) · Immunology Letters · doi:10.1016/j.imlet.2016.05.007 · Cited by 46 · cited 1×
“NKs are able to detect and kill cells that have lost or under-expressed humanleukocytes antigen (HLA) class I, which is a common feature observed in tumour cells and virus-infected cells [47].”
BackgroundFusco, N., Vaira, V., Righi, I., Sajjadi, E., Venetis, K., Lopez, G., Cattaneo, M., Castellani, M., Rosso, L., Nosotti, M., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.09.026 · Cited by 46 · cited 7×
“TILs are highly expressed in both peritumoral and stromal compartment of epithelioid and sarcomatoid MPM [62].”
BackgroundResultInfluentialChen, N., Liu, S., Huang, L., Li, W., Yang, W., Cong, T., Ding, L., & Qiu, M. (2017) · Oncotarget · doi:10.18632/oncotarget.15404 · Cited by 42 · cited 2×
“In addition, systemic inflammation is important to consider as it has been reported to be associated with poor prognosis in several tumours [91] and it is estimated that approximately 30% of patients with MPM experienced symptoms related to systemic inflammation such as fever, weight loss, asthenia and night sweats [9…”
BackgroundGhanim, B., Klikovits, T., Hoda, M. A., Láng, G., Szirtes, I., Setinek, U., Rózsás, A., Renyi-Vamos, F., László, V., Grusch, M., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.9 · Cited by 41 · cited 1×
“High proliferation index, as expressed by Ki-67, was an independent factor of poor survival in patients with epithelioid mesothelioma in a cohort of 187 patients [53].”
BackgroundLow-Dose Cyclophosphamide Synergizes with Dendritic Cell-Based Immunotherapy in Antitumor Activity
Veltman, J. D., Lambers, M. E. H., van Nimwegen, M., de Jong, S., Hendriks, R. W., Hoogsteden, H. C., Aerts, J. G. J. V., & Hegmans, J. P. J. J. (2010) · Journal of Biomedicine and Biotechnology · doi:10.1155/2010/798467 · Cited by 41
Sottile, R., Tannazi, M., Johansson, M. H., Cristiani, C. M., Calabró, L., Ventura, V., Cutaia, O., Chiarucci, C., Covre, A., Garofalo, C., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32363 · Cited by 38 · cited 21×
“As an assessment of immunotolerance in the microenvironment, a strong correlation was found between the expression of TIM-3 and PDL-1 on TILs in the stroma (RR = 0.48; p < 0.001) [40].”
BackgroundInfluentialHabougit, C., Trombert‐Paviot, B., Karpathiou, G., Casteillo, F., Bayle-Bleuez, S., Fournel, P., Vergnon, J., Tiffet, O., Péoc’h, M., & Forest, F. (2017) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-017-2109-z · Cited by 37 · cited 1×
“Moreover, in the epithelioid subtype, mitotic count, necrosis, nuclear atypia and nucleoli size were found to be independent prognostic factors of overall survival [10].”
BackgroundSelf-citationExtracellular vesicles as biomarkers in malignant pleural mesothelioma: A review
Ahmadzada, T., Kao, S., Reid, G., Clarke, S. J., Grau, G. E., & Hosseini‐Beheshti, E. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102949 · Cited by 35
Inflammation in malignant mesothelioma - friend or foe?
Linton, A., van Zandwijk, N., Reid, G., Clarke, S. J., Cao, C. Q., & Kao, S. (2012) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2225-319x.2012.10.02 · Cited by 32 · cited 2×
“In addition, systemic inflammation is important to consider as it has been reported to be associated with poor prognosis in several tumours [91] and it is estimated that approximately 30% of patients with MPM experienced symptoms related to systemic inflammation such as fever, weight loss, asthenia and night sweats [9…”
BackgroundMethodPylkkänen, L., Sainio, M. A., Ollikainen, T., Mattson, K. V., Nordling, S., Carpén, O., Linnainmaa, K., & Husgafvel‐Pursiainen, K. (2002) · Oncology Reports · doi:10.3892/or.9.5.955 · Cited by 29
Lemos, L. G. T., Victorino, V. J., Herrera, A. C. S. A., Aranome, A. M. F., Cecchini, A. L., Simão, A. N. C., Panis, C., & Cecchini, R. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.04.037 · Cited by 28 · cited 1×
“The therapeutic functions can be emphasized by targeting certain surface Ags of lymphocytes, such as CD40 [64], CD20 [65], CD19 [66], CD73 [67], CTLA-4 or PD-1 immune checkpoints [68], blocking the binding of specific ligands, and perturbing the EGFR and HER2 signaling pathways [69,70].”
BackgroundNishimura, Y., Kumagai-Τakei, N., Matsuzaki, H., Lee, S. P., Maeda, M., Kishimoto, T., Fukuoka, K., Nakano, T., & Otsuki, T. (2015) · BioMed Research International · doi:10.1155/2015/238431 · Cited by 27 · cited 1×
“Although NKs have been found to constitute a major part of inflammatory cells’ infiltration in MPM [33], it seems that—similar to DCs—NKs present functional alterations in MPM [46].”
BackgroundWu, L., Yun, Z., Tagawa, T., de la Maza, L. M., Wu, M. O., Yu, J. L., Zhao, Y. D., & de Perrot, M. E. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1597-9 · Cited by 27 · cited 4×
“In CD1d wild-type xenograft models, after sub-cutaneous injection of AB12 cell lines—a murine malignant mesothelioma cell line derived from asbestos-induced tumour in Balb/c mice [52]—tumour growth was decreased by the combination of α-GC following each cycle of cisplatin [51].”
BackgroundInfluentialCornwall, S. M. J., Wikström, M. E., Musk, A. W., Alvarez, J. D., Nowak, A. K., & Nelson, D. J. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1082028 · Cited by 27 · cited 3×
“, 2016 [42] 48 Dendritic cells (DC) MPM vs.”
BackgroundResultKohno, M., Murakami, J., Wu, L., Chan, M.-L., Yun, Z., Cho, J., & de Perrot, M. E. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000487 · Cited by 27 · cited 9×
“In this model, depletion of FOXP3 was associated with upregulation of immune checkpoint expression (PD-1 and CTLA-4) on CD4+ and CD8+ TILs and a central memory T-cells pattern (CD44 + CD62L + CD4+ T-cells and CD44 + CD62L + CD8+ T-cells) [86].”
BackgroundMethodInfluentialÖnür, S. T., Sökücü, S. N., Dalar, L., İliaz, S., Kara, K., Büyükkale, S., & Altın, S. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s104077 · Cited by 26
(2015) · PubMed Central · doi:10.3978/j.issn.2072-1439.2015.11.15 · Cited by 24 · cited 3×
“On the contrary, NLR was not identified as an independent prognostic biomarker [96].”
BackgroundResultInfluentialTolani, B., Acevedo, L. A., Hoang, N. T., & He, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010238 · Cited by 23 · cited 4×
“Evidence suggests that in MPM, adaptative immune cells—CD4+ helper T-cells and CD8+ cytotoxic T-cells—are mainly expressed in the stromal compartment of the tumour, whereas regulatory T-cells border the tumour cells [43,58].”
BackgroundInfluentialLosi, L., Bertolini, F., Guaitoli, G., Fabbiani, L., Banchelli, F., Ambrosini‐Spaltro, A., Botticelli, L., Scurani, L., Baldessari, C., Barbieri, F., et al. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4883 · Cited by 22 · cited 6×
“observed a trend between low lymphocytic infiltration at diagnosis as well as high CD8+ TILs expression and poorer prognosis [83].”
BackgroundResultInfluentialAhmadzada, T., Lee, K. M. L., Clarke, C. J., Cooper, W. A., Linton, A., McCaughan, B. C., Asher, R., Clarke, S. J., Reid, G., & Kao, S. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.02.005 · Cited by 21 · cited 2×
“observed that most patients had inflamed immune tumour with CD3 expression (CD3+ positive ≥1%; 75% of patients) within the tumour [90].”
BackgroundExpression status of PD‐L1 and B7‐H3 in mesothelioma
Matsumura, E., Kajino, K., Abe, M., Ohtsuji, N., Saeki, H., Hlaing, M. T., & Hino, O. (2020) · Pathology International · doi:10.1111/pin.13028 · Cited by 20
Lievense, L. A., Bezemer, K., Cornelissen, R., Kaijen-Lambers, M. E. H., Hegmans, J. P., & Aerts, J. G. J. V. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.04.015 · Cited by 19 · cited 2×
“compared the immune compositions of pleural effusions and tumour biopsies from five patients with an MPM [88].”
BackgroundResultLee, S. P., Matsuzaki, H., Maeda, M., Yamamoto, S., Kumagai-Τakei, N., Hatayama, T., Ikeda, M., Yoshitome, K., Nishimura, Y., & Otsuki, T. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3776 · Cited by 17 · cited 4×
“Moreover, in vitro experiments on MT-2 human polyclonal Tcells with chronic exposure to asbestos fibres revealed that regulatory T-cells have enhanced functions through high expression of interleukin-10 and Transforming Growth Factor-betta (TGF-β) [19].”
BackgroundInfluentialCritical Roles of Tumor Extracellular Vesicles in the Microenvironment of Thoracic Cancers
Kara-Terki, L., Treps, L., Blanquart, C., & Fradin, D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176024 · Cited by 17
von Muenchow, L., Engdahl, C., Karjalainen, K., & Rolink, A. G. (2014) · Immunology Letters · doi:10.1016/j.imlet.2014.01.011 · Cited by 12 · cited 5×
“On the contrary, the analysis of 88 MPM patient samples who underwent chemotherapy or extended pleurectomy/decortication alone or in a context of multimodality treatment, revealed that CD19+ B-cells and CD4+ stromal TILs were significantly enhanced (respectively, p = 0.02 and p = 0.01) in sarcomatoid MPM [62].”
BackgroundInfluentialInduction of IL-17 production from human peripheral blood CD4+ cells by asbestos exposure
Maeda, M., Chen, Y., Lee, S. P., Kumagai-Τakei, N., Yoshitome, K., Matsuzaki, H., Yamamoto, S., Hatayama, T., Ikeda, M., Nishimura, Y., et al. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.3991 · Cited by 12 · cited 1×
“, the chemokine receptor on the surface of T helper cells) and the production of Interferon gamma (IFN-γ) were reduced in peripheral CD4+-cells of asbestos-exposed patients [18].”
BackgroundMarcq, E., Audenaerde, J. R. M. V., Waele, J. D., Jacobs, J., Loenhout, J. V., Cavents, G., Pauwels, P., van Meerbeeck, J. P., & Smits, E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174182 · Cited by 12
Rrapaj, E., Giacometti, L., Spina, P., Salvo, M., Baselli, G., Veggiani, C., Rena, O., Trisolini, E., & Boldorini, R. L. (2020) · Pathology · doi:10.1016/j.pathol.2020.09.018 · Cited by 11 · cited 2×
“Rrapaj, 2021 [104] 198 PD-L1 and overall survival (OS) Tissue biopsy Immunohistoche mistry PD-L1 > 5% PD-L1 positive cases were associated with poor OS”
BackgroundLosi, L., Bertolini, F., Scurani, L., Guaitoli, G., Baldessari, C., Spaltro, A. A., Botticelli, L., Maiorana, A., Barbieri, F., & Cascinu, S. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy301.002 · Cited by 10
Significance of Fas and FasL protein expression in cardiac carcinoma and local lymph node tissues.
Li, Y., Xu, D., Jiang, D., Zhao, J., Ge, J.-F., & Zheng, S. (2015) · PubMed Central · Cited by 7
Mansour, M. S. I., Seidal, T., Mager, U., Dobra, K., Brunnström, H., & Dejmek, A. (2021) · Cancer Cytopathology · doi:10.1002/cncy.22401 · Cited by 4
Chen, Y., Chen, L., Lu, Q., Meng, Y., Wang, C., Wang, L., Wang, H., Yu, X., Zhang, Y., Zhao, L., et al. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.02.158 · Cited by 3 · cited 1×
“The therapeutic functions can be emphasized by targeting certain surface Ags of lymphocytes, such as CD40 [64], CD20 [65], CD19 [66], CD73 [67], CTLA-4 or PD-1 immune checkpoints [68], blocking the binding of specific ligands, and perturbing the EGFR and HER2 signaling pathways [69,70].”
Background(2003) · PubMed
Cited by
Mesothelioma Malignancy and the Microenvironment: Molecular Mechanisms
Cersosimo, F., Barbarino, M., Lonardi, S., Vermi, W., Giordano, A., Bellan, C., & Giurisato, E. (2021) · Cancers · doi:10.3390/cancers13225664 · Cited by 41
“Phagocytic macrophages, unable to eliminate fibers, release oxidative molecules and pro-inflammatory cytokines that promote a pro-inflammatory environment and activate signaling pathways in tumor cells that help them to survive despite the asbestos-related damage [80].”
BackgroundPonce, S., Cedrés, S., Ricordel, C., Isambert, N., Viteri, S., Herrera, M., Martínez‐Martí, A., Navarro, A., Léderlin, M., Serres, X., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007552 · Cited by 46
Theranostic signature of tumor-derived exosomes in cancer
Kumar, S., Dhar, R., Kumar, L., Shivji, G. G., Jayaraj, R., & Devi, A. (2023) · Medical Oncology · doi:10.1007/s12032-023-02176-6 · Cited by 37
Fiorilla, I., Martinotti, S., Todesco, A. M., Bonsignore, G., Cavaletto, M., Patrone, M., Ranzato, E., & Audrito, V. (2023) · Cells · doi:10.3390/cells12162048 · Cited by 39
Perrino, M., Vincenzo, F. D., Cordua, N., Borea, F., Aliprandi, M., Santoro, A., & Zucali, P. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1121557 · Cited by 35
Metadata
- Authors
- Désage, A.-L., Karpathiou, G., Peoc’h, M., & Froudarakis, M. E.
- Affiliations
- Centre Hospitalier Universitaire de Saint-Étienne (FR)
- Pathology, North Hospital, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France
- Department of Pulmonology and Thoracic Oncology, North Hospital, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-06-26
- Volume
- 13
- Issue
- 13
- Pages
- 3205
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC8269097
- OpenAlex
- W3175991011
- Cited by
- 34
- References
- 165
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 3 · 2023: 9 · 2022: 7 · 2021: 2
- FWCI
- 0.84
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- malignant pleural mesothelioma, tumor immune microenvironment, tumour-associated macrophages, M2 macrophages, immunosuppression, dendritic cells, natural killer cells, tumor-infiltrating lymphocytes, regulatory T cells, immune checkpoint, asbestos exposure, immunotherapy targets
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.